149 related articles for article (PubMed ID: 19497737)
21. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors.
Das D; Hong J; Chen SH; Wang G; Beigelman L; Seiwert SD; Buckman BO
Bioorg Med Chem; 2011 Aug; 19(16):4690-703. PubMed ID: 21798747
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives as novel HCV inhibitors.
Kang IJ; Wang LW; Hsu SJ; Lee CC; Lee YC; Wu YS; Hsu TA; Yueh A; Chao YS; Chern JH
Bioorg Med Chem Lett; 2009 Aug; 19(15):4134-8. PubMed ID: 19539472
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring.
Rockway TW; Zhang R; Liu D; Betebenner DA; McDaniel KF; Pratt JK; Beno D; Montgomery D; Jiang WW; Masse S; Kati WM; Middleton T; Molla A; Maring CJ; Kempf DJ
Bioorg Med Chem Lett; 2006 Jul; 16(14):3833-8. PubMed ID: 16650984
[TBL] [Abstract][Full Text] [Related]
24. Effects of the aryl linker and the aromatic substituent on the anti-HCV activities of aryl diketoacid (ADK) analogues.
Kim J; Kim KS; Lee HS; Park KS; Park SY; Kang SY; Lee SJ; Park HS; Kim DE; Chong Y
Bioorg Med Chem Lett; 2008 Aug; 18(16):4661-5. PubMed ID: 18644717
[TBL] [Abstract][Full Text] [Related]
25. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.
Li LS; Zhou Y; Murphy DE; Stankovic N; Zhao J; Dragovich PS; Bertolini T; Sun Z; Ayida B; Tran CV; Ruebsam F; Webber SE; Shah AM; Tsan M; Showalter RE; Patel R; Lebrun LA; Bartkowski DM; Nolan TG; Norris DA; Kamran R; Brooks J; Sergeeva MV; Kirkovsky L; Zhao Q; Kissinger CR
Bioorg Med Chem Lett; 2008 Jun; 18(11):3446-55. PubMed ID: 18457949
[TBL] [Abstract][Full Text] [Related]
26. Studies on acyl pyrrolidine inhibitors of HCV RNA-dependent RNA polymerase to identify a molecule with replicon antiviral activity.
Burton G; Ku TW; Carr TJ; Kiesow T; Sarisky RT; Lin-Goerke J; Hofmann GA; Slater MJ; Haigh D; Dhanak D; Johnson VK; Parry NR; Thommes P
Bioorg Med Chem Lett; 2007 Apr; 17(7):1930-3. PubMed ID: 17270443
[TBL] [Abstract][Full Text] [Related]
27. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 2: Variation of the 2- and 6-pyridazinone substituents.
Zhou Y; Li LS; Dragovich PS; Murphy DE; Tran CV; Ruebsam F; Webber SE; Shah AM; Tsan M; Averill A; Showalter RE; Patel R; Han Q; Zhao Q; Hermann T; Kissinger CR; Lebrun L; Sergeeva MV
Bioorg Med Chem Lett; 2008 Feb; 18(4):1419-24. PubMed ID: 18226901
[TBL] [Abstract][Full Text] [Related]
28. Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase.
Donner PL; Xie Q; Pratt JK; Maring CJ; Kati W; Jiang W; Liu Y; Koev G; Masse S; Montgomery D; Molla A; Kempf DJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2735-8. PubMed ID: 18362072
[TBL] [Abstract][Full Text] [Related]
29. Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors.
Zhao C; Wang Y; Ma S
Eur J Med Chem; 2015 Sep; 102():188-214. PubMed ID: 26276434
[TBL] [Abstract][Full Text] [Related]
30. Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.
Kim SH; Tran MT; Ruebsam F; Xiang AX; Ayida B; McGuire H; Ellis D; Blazel J; Tran CV; Murphy DE; Webber SE; Zhou Y; Shah AM; Tsan M; Showalter RE; Patel R; Gobbi A; LeBrun LA; Bartkowski DM; Nolan TG; Norris DA; Sergeeva MV; Kirkovsky L; Zhao Q; Han Q; Kissinger CR
Bioorg Med Chem Lett; 2008 Jul; 18(14):4181-5. PubMed ID: 18554907
[TBL] [Abstract][Full Text] [Related]
31. Novel 4-thiazolidinones as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase.
Çakir G; Küçükgüzel İ; Guhamazumder R; Tatar E; Manvar D; Basu A; Patel BA; Zia J; Talele TT; Kaushik-Basu N
Arch Pharm (Weinheim); 2015 Jan; 348(1):10-22. PubMed ID: 25449674
[TBL] [Abstract][Full Text] [Related]
32. Allosteric inhibitors of hepatitis C virus NS5B polymerase thumb domain site II: structure-based design and synthesis of new templates.
Malancona S; Donghi M; Ferrara M; Martin Hernando JI; Pompei M; Pesci S; Ontoria JM; Koch U; Rowley M; Summa V
Bioorg Med Chem; 2010 Apr; 18(8):2836-48. PubMed ID: 20363140
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors.
Raboisson P; Lenz O; Lin TI; Surleraux D; Chakravarty S; Scholliers A; Vermeiren K; Delouvroy F; Verbinnen T; Simmen K
Bioorg Med Chem Lett; 2007 Apr; 17(7):1843-9. PubMed ID: 17289388
[TBL] [Abstract][Full Text] [Related]
34. Pyridobenzothiazole derivatives as new chemotype targeting the HCV NS5B polymerase.
Manfroni G; Meschini F; Barreca ML; Leyssen P; Samuele A; Iraci N; Sabatini S; Massari S; Maga G; Neyts J; Cecchetti V
Bioorg Med Chem; 2012 Jan; 20(2):866-76. PubMed ID: 22197397
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors of hepatitis C virus polymerase: synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides.
Cheng CC; Shipps GW; Yang Z; Kawahata N; Lesburg CA; Duca JS; Bandouveres J; Bracken JD; Jiang CK; Agrawal S; Ferrari E; Huang HC
Bioorg Med Chem Lett; 2010 Apr; 20(7):2119-24. PubMed ID: 20219368
[TBL] [Abstract][Full Text] [Related]
36. Non-nucleoside benzimidazole-based allosteric inhibitors of the hepatitis C virus NS5B polymerase: inhibition of subgenomic hepatitis C virus RNA replicons in Huh-7 cells.
Beaulieu PL; Bousquet Y; Gauthier J; Gillard J; Marquis M; McKercher G; Pellerin C; Valois S; Kukolj G
J Med Chem; 2004 Dec; 47(27):6884-92. PubMed ID: 15615537
[TBL] [Abstract][Full Text] [Related]
37. Cyclic amide bioisosterism: strategic application to the design and synthesis of HCV NS5B polymerase inhibitors.
Yang H; Hendricks RT; Arora N; Nitzan D; Yee C; Lucas MC; Yang Y; Fung A; Rajyaguru S; Harris SF; Leveque VJ; Hang JQ; Pogam SL; Reuter D; Tavares GA
Bioorg Med Chem Lett; 2010 Aug; 20(15):4614-9. PubMed ID: 20584604
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of lactam-thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors.
Barnes-Seeman D; Boiselle C; Capacci-Daniel C; Chopra R; Hoffmaster K; Jones CT; Kato M; Lin K; Ma S; Pan G; Shu L; Wang J; Whiteman L; Xu M; Zheng R; Fu J
Bioorg Med Chem Lett; 2014 Aug; 24(16):3979-85. PubMed ID: 24986660
[TBL] [Abstract][Full Text] [Related]
39. II. Novel HCV NS5B polymerase inhibitors: discovery of indole C2 acyl sulfonamides.
Anilkumar GN; Selyutin O; Rosenblum SB; Zeng Q; Jiang Y; Chan TY; Pu H; Wang L; Bennett F; Chen KX; Lesburg CA; Duca J; Gavalas S; Huang Y; Pinto P; Sannigrahi M; Velazquez F; Venkatraman S; Vibulbhan B; Agrawal S; Ferrari E; Jiang CK; Huang HC; Shih NY; George Njoroge F; Kozlowski JA
Bioorg Med Chem Lett; 2012 Jan; 22(1):713-7. PubMed ID: 22104146
[TBL] [Abstract][Full Text] [Related]
40. A cell-based assay for RNA synthesis by the HCV polymerase reveals new insights on mechanism of polymerase inhibitors and modulation by NS5A.
Ranjith-Kumar CT; Wen Y; Baxter N; Bhardwaj K; Cheng Kao C
PLoS One; 2011; 6(7):e22575. PubMed ID: 21799903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
